A Study of the Online ASCENT Survivorship Care Plan in Patients with Prostate Cancer Receiving Radiotherapy and Hormonal Therapy

Share
Print

Full Title

Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients with Prostate Cancer Undergoing Curative-Intent Radiotherapy with Concurrent Androgen Deprivation Therapy (ADT)

Purpose

Men with prostate cancer undergoing radiation therapy usually have their cancer treatment managed by a radiation oncologist. The radiation oncologist works directly with the patient’s primary care physician (PCP) to manage any long-term side effects from the cancer treatment. In this study, researchers want to see if an internet-based tool that shares information about prostate cancer care between a man with prostate cancer and his care providers can improve communication between cancer specialists and PCPs.

Participants in this study will be assigned to one of two study groups. One group will use an online communications system called ASCENT to help manage their care. The other group will have their care managed in the usual way (as described above). ASCENT includes the patient’s customized care plan, outlines the patient’s healthcare needs, features a patient resources navigator who helps patients access support services, and sends periodic reminders to patients to follow their recommended plan of care.

Patients in the ASCENT group will have their care plan shared with their PCPs via fax from the ASCENT system. Patients who are not in the ASCENT group will have standard communication between the radiation oncologist and PCP and will also have access to the online resources of the ASCENT system. All patients will complete surveys about their experiences 6 months after joining the study.

Eligibility

This study is open to men age 18 or older having radiation therapy as well as androgen deprivation (hormonal) therapy for prostate cancer.

For more information about this study, please contact Dr. Sigrid Carlsson at 646-888-8250 or Dr. Sean McBride at 212-639-5717.

Protocol

19-076

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Carlsson, Sigrid, MD, PhD, MPH

Co-Investigators